(Q33379246)

English

Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

5

object named as

Yung-Jue Bang

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Hyo-Pyo Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sang-Soo Seo

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sang-Young Ryu

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jong-Hyeok Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sang-Yoon Park

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joo-Hyun Nam

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Soon-Beom Kang

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kyung-Hee Lee

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yong Sang Song

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

10 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

109

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

359-363

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Designs for group sequential phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.11.023

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.11.023

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33379246&oldid=1686971777"